Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database-Reference-Cited by-同舟云学术

Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database

Published:2021-08 Issue:2 Volume:162 Page:496-505
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Ma Zhuo,Sun Ximu,Zhao Zhixia,Lu Wenchao,Guo Qixiang,Wang Shihao,You Jiwen,Zhang Yuhui,Liu Lihong

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference47 articles.

1. A decade of clinical development of PARP inhibitors in perspective;Mateo;Ann. Oncol.,2019

2. Incorporating PARP-inhibitors in primary and recurrent ovarian cancer: a meta analysis of 12 phase II/III randomized controlled trials;Ruscito;Cancer Treat. Rev.,2020

3. Exploring and comparing adverse events between PARP inhibitors;LaFargue;Lancet Oncol.,2019

4. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials;Ruiz-Schutz;Crit. Rev. Oncol. Hematol.,2019

5. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials;Liu;Drug Des Devel Ther.,2018

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and radiological pattern of olaparib-induced interstitial lung disease;BMC Pulmonary Medicine;2024-09-13

2. Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database;Expert Opinion on Drug Safety;2024-08

3. Clinical and radiological pattern of olaparib- induced interstitial lung disease;2024-07-23

4. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system;Frontiers in Pharmacology;2024-07-10

5. Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy;Clinical Lung Cancer;2024-07